Comparative Pharmacology
Head-to-head clinical analysis: LODINE versus MEPROBAMATE AND ASPIRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE versus MEPROBAMATE AND ASPIRIN.
LODINE vs MEPROBAMATE AND ASPIRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
Meprobamate is a carbamate derivative that acts as a CNS depressant, potentiating GABA-A receptor activity and inhibiting polysynaptic spinal reflexes. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
Aspirin 325 mg and meprobamate 200 mg orally every 6 to 8 hours as needed for pain or anxiety. Maximum daily dose: aspirin 3.9 g, meprobamate 1.6 g.
None Documented
None Documented
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Aspirin: 15-20 minutes (parent drug), but salicylate half-life is dose-dependent: 2-3 hours for low doses, 15-30 hours for high doses. Meprobamate: 6-17 hours (mean 10 hours), prolonged in overdose or hepatic impairment.
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Aspirin: Renal excretion of salicylates (75% as salicyluric acid, 10% as salicylic acid, 10% as phenolic glucuronide, 5% as acyl glucuronide). Meprobamate: Renal excretion (10-20% unchanged, 80-90% as hydroxylated metabolites) and biliary excretion (<5%).
Category C
Category D/X
NSAID
NSAID / Antiplatelet